HOME > TOP STORIES

TOP STORIES

BUSINESS Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President

January 29, 2025
REGULATORY LDP-OK’ed Bill for PMD Act Amendment Specifies Launch of Innovative Drug Fund

January 28, 2025
BUSINESS Sanofi Stages V-Shaped Recovery in Vaccine Biz, Set for Growth with New Products Beyond Hib

January 27, 2025
BUSINESS MHLW Planning 10-Year Fund for Drug Discovery, Official Reveals at JPMA Meeting

January 24, 2025
REGULATORY MHLW Eyes 2 Biz Models as It Pushes Generic Industry Shakeup: Minister

January 23, 2025
BUSINESS Sanofi CEO Warns Off-Cycle Price Cuts Will Dilute Attractiveness of Japan Market

January 22, 2025
REGULATORY Astellas’ Xtandi on 2nd Drug List Up for IRA Price Negotiations

January 21, 2025
BUSINESS Nxera’s 50 Billion Yen Global Sales Goal “Conservative Figure”: Japan Chief

January 20, 2025
BUSINESS Industry Appreciates Raise in Minimum NHI Prices, but See It as Mere Drop in Bucket

January 17, 2025
REGULATORY 3 JAK Inhibitors, Wegovy and More Drugs Enjoy First Off-Year Application of Post-Launch Premiums

January 16, 2025
REGULATORY Govt Must Not Let Pro-Innovation Reform of 2024 Go to Waste: Sr Vice Minister

January 15, 2025
BUSINESS SGLT2 Inhibitor Forxiga Braced for Generic Entry in 2025

January 14, 2025
BUSINESS Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential

January 10, 2025
COMMENTARY Japan Expects to Approve/List 43 Novel Drugs in 2025 Including Ultra-Expensive Gene Therapies

January 9, 2025
ORGANIZATION Pharma CEOs Discouraged by Off-Year Revision, but Give Certain Credit to Category-Based Scope

January 9, 2025
REGULATORY MHLW Official Reveals Rationales Behind Off-Year Decision, Says PMP Return Is Reasonable

January 8, 2025
BUSINESS Daiichi Sankyo to Transfer Avastin Biosimilar to Amgen in Japan

January 8, 2025
ORGANIZATION 4-Ministers’ Pact Has Effectively Been Scrapped with 2025 Off-Year Revision Plan: FPMAJ Chair

January 7, 2025
ORGANIZATION As 2025 Begins, Industry Leaders Renew Resolve towards Next Reforms

January 6, 2025
REGULATORY Japan Approves Zepbound, Qalsody, and Lots More Drugs

December 27, 2024

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…